NCT00064129View on ClinicalTrials.gov

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 13, 2003

Primary Completion Date

January 10, 2011

Study Completion Date

October 1, 2012

Conditions
Recurrent Prostate CarcinomaStage IV Prostate Cancer AJCC v7
Interventions
BIOLOGICAL

Ipilimumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

BIOLOGICAL

Sargramostim

Given SC

Trial Locations (1)

94115

UCSF Medical Center-Mount Zion, San Francisco

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00064129 - Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter